258 related articles for article (PubMed ID: 24319212)
1. Lymphocyte-predominant Hodgkin lymphoma: what is the optimal treatment?
Fanale M
Hematology Am Soc Hematol Educ Program; 2013; 2013():406-13. PubMed ID: 24319212
[TBL] [Abstract][Full Text] [Related]
2. [Nodular lymphocyte-predominant Hodgkin lymphoma in children: clinical course, biology, and management].
Gorde-Grosjean S; Guimard G; Lambilliotte A; Coulomb-Lhermine A; Montravers F; Landman-Parker J
Bull Cancer; 2014 Sep; 101(9):881-90. PubMed ID: 25296072
[TBL] [Abstract][Full Text] [Related]
3. CD20-negative T-cell-rich B-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximab: a molecular analysis using laser capture microdissection.
Pijuan L; Vicioso L; Bellosillo B; Ferrer MD; Baró T; Pedro C; Lloreta-Trull J; Munné A; Serrano S
Am J Surg Pathol; 2005 Oct; 29(10):1399-403. PubMed ID: 16160485
[TBL] [Abstract][Full Text] [Related]
4. CD20-Negative Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A 20-Year Consecutive Case Series From a Tertiary Cancer Center.
Menke JR; Spinner MA; Natkunam Y; Warnke RA; Advani RH; Gratzinger DA
Arch Pathol Lab Med; 2021 Jun; 145(6):753-758. PubMed ID: 32991677
[TBL] [Abstract][Full Text] [Related]
5. How I treat nodular lymphocyte predominant Hodgkin lymphoma.
Advani RH; Hoppe RT
Blood; 2013 Dec; 122(26):4182-8. PubMed ID: 24215035
[TBL] [Abstract][Full Text] [Related]
6. The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma.
Maeda LS; Advani RH
Curr Opin Oncol; 2009 Sep; 21(5):397-400. PubMed ID: 19606035
[TBL] [Abstract][Full Text] [Related]
7. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG).
Schulz H; Rehwald U; Morschhauser F; Elter T; Driessen C; Rüdiger T; Borchmann P; Schnell R; Diehl V; Engert A; Reiser M
Blood; 2008 Jan; 111(1):109-11. PubMed ID: 17938252
[TBL] [Abstract][Full Text] [Related]
8. Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma.
Advani RH; Horning SJ; Hoppe RT; Daadi S; Allen J; Natkunam Y; Bartlett NL
J Clin Oncol; 2014 Mar; 32(9):912-8. PubMed ID: 24516013
[TBL] [Abstract][Full Text] [Related]
9. J chain and myocyte enhancer factor 2B are useful in differentiating classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.
Moore EM; Swerdlow SH; Gibson SE
Hum Pathol; 2017 Oct; 68():47-53. PubMed ID: 28851661
[TBL] [Abstract][Full Text] [Related]
10. Modern principles in the management of nodular lymphocyte-predominant Hodgkin lymphoma.
Spinner MA; Varma G; Advani RH
Br J Haematol; 2019 Jan; 184(1):17-29. PubMed ID: 30485408
[TBL] [Abstract][Full Text] [Related]
11. Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique management.
Eichenauer DA; Engert A
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):324-328. PubMed ID: 29222274
[TBL] [Abstract][Full Text] [Related]
12. Management of nodular lymphocyte predominant Hodgkin lymphoma in the modern era.
King MT; Donaldson SS; Link MP; Natkunam Y; Advani RH; Hoppe RT
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):67-75. PubMed ID: 25863755
[TBL] [Abstract][Full Text] [Related]
13. Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group.
Eichenauer DA; Fuchs M; Pluetschow A; Klimm B; Halbsguth T; Böll B; von Tresckow B; Nogová L; Borchmann P; Engert A
Blood; 2011 Oct; 118(16):4363-5. PubMed ID: 21828141
[TBL] [Abstract][Full Text] [Related]
14. Biology, clinical course and management of nodular lymphocyte-predominant hodgkin lymphoma.
Nogová L; Rudiger T; Engert A
Hematology Am Soc Hematol Educ Program; 2006; ():266-72. PubMed ID: 17124071
[TBL] [Abstract][Full Text] [Related]
15. Nodular lymphocyte-predominant hodgkin lymphoma.
Tsai HK; Mauch PM
Semin Radiat Oncol; 2007 Jul; 17(3):184-9. PubMed ID: 17591565
[TBL] [Abstract][Full Text] [Related]
16. Nodular lymphocyte-predominant Hodgkin lymphoma.
Fuchs M; Eichenauer DA; Nogová L; Diehl V; Engert A;
Curr Hematol Malig Rep; 2008 Jul; 3(3):126-31. PubMed ID: 20425457
[TBL] [Abstract][Full Text] [Related]
17. The unique entity of nodular lymphocyte-predominant Hodgkin lymphoma: current approaches to diagnosis and management.
Hawkes EA; Wotherspoon A; Cunningham D
Leuk Lymphoma; 2012 Mar; 53(3):354-61. PubMed ID: 21812538
[TBL] [Abstract][Full Text] [Related]
18. Characteristics and outcomes of patients with nodular lymphocyte-predominant Hodgkin lymphoma versus those with classical Hodgkin lymphoma: a population-based analysis.
Gerber NK; Atoria CL; Elkin EB; Yahalom J
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):76-83. PubMed ID: 25863756
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Where Do We Stand? Where Do We Go?
Eichenauer DA; Fuchs M
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444420
[TBL] [Abstract][Full Text] [Related]
20. Nodular lymphocyte-predominant Hodgkin lymphoma: current management strategies and evolving approaches to individualize treatment.
Eichenauer DA; Hartmann S
Expert Rev Hematol; 2023; 16(8):607-615. PubMed ID: 37337881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]